Human monocytes undergo spontaneous apoptosis upon culture in vitro; removal of serum from the media dramatically increases the rate of this process. Monocyte apoptosis can be significantly abrogated by the addition of growth factors or proinflammatory mediators. We have evaluated the role of the endogenous Fas–Fas ligand (FasL) interaction in the induction of this spontaneous apoptosis and found that a Fas–immunoglobulin (Ig) fusion protein, an antagonistic anti-Fas monoclonal antibody and a rabbit anti-FasL antibody all greatly reduced the onset of apoptosis. The results indicate that spontaneous death of monocytes is mediated via an autocrine or paracrine pathway. Treatment of the cells with growth factors or cytokines that prevented spontaneous apoptosis had no major effects on the expression of Fas or FasL. Additionally, monocyte-derived macrophages were found to express both Fas and FasL but did not undergo spontaneous apoptosis and were not sensitive to stimulation by an agonistic anti-Fas IgM. These results indicate that protective mechanisms in these cells exist at a site downstream of the receptor–ligand interaction.
Skip Nav Destination
Article navigation
21 April 1997
Brief Definitive Report|
April 21 1997
Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages
Peter A. Kiener,
Peter A. Kiener
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
Patricia M. Davis,
Patricia M. Davis
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
Gary C. Starling,
Gary C. Starling
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
Christopher Mehlin,
Christopher Mehlin
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
Seymour J. Klebanoff,
Seymour J. Klebanoff
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
Jeffrey A. Ledbetter,
Jeffrey A. Ledbetter
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
W. Conrad Liles
W. Conrad Liles
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Search for other works by this author on:
Peter A. Kiener
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Patricia M. Davis
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Gary C. Starling
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Christopher Mehlin
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Seymour J. Klebanoff
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Jeffrey A. Ledbetter
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
W. Conrad Liles
From the *Immunological Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121; ‡Department of Pathobiology and the §Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195
Address correspondence to Peter A. Kiener, Bristol-Myers Squibb Pharmaceutical Research Institute, 3005 First Avenue, Seattle, Washington 98121.
W.C. Liles is a Pfizer Postdoctoral fellow.
Received:
January 09 1997
Revision Received:
February 24 1997
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1997
J Exp Med (1997) 185 (8): 1511–1516.
Article history
Received:
January 09 1997
Revision Received:
February 24 1997
Citation
Peter A. Kiener, Patricia M. Davis, Gary C. Starling, Christopher Mehlin, Seymour J. Klebanoff, Jeffrey A. Ledbetter, W. Conrad Liles; Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages. J Exp Med 21 April 1997; 185 (8): 1511–1516. doi: https://doi.org/10.1084/jem.185.8.1511
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement